A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia

ClinicalTrials.gov processed this data on June 25, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

COMPLETED (See Contacts and Locations)
Verified June 2024 by Otsuka Pharmaceutical Development & Commercialization, Inc.

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Information Provided by (Responsible Party)

Otsuka Pharmaceutical Development & Commercialization, Inc.

Clinicaltrials.gov Identifier

NCT04092686
Other Study ID Numbers: 361-302
First Submitted: September 13, 2019
First Posted: September 17, 2019
Last Update Posted: June 26, 2024
Last Verified: June 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

This is a multicenter, randomized, double-blind, parallel-group, fixed-dosed study evaluating the efficacy and safety of two doses of SEP-363856 (75 and 100 mg/day) versus placebo over a 6-week Treatment Period in acutely psychotic subjects with schizophrenia. This study is projected to randomize approximately 462 subjects to 3 treatment groups (SEP-363856 75 mg/day, SEP-363856 100 mg/day, or placebo) in a 1:1:1 ratio. Treatment assignment will be stratified by country. Study drug will be taken once a day and may be taken with or without food.

This study is designed to test the hypotheses that treatment with SEP-363856 in adult subjects with schizophrenia will result in significantly greater reduction (i.e. improvement) in PANSS total score and CGI-S score at Week 6 from Baseline when compared to placebo. The overall Type I error is controlled for two hierarchical families of hypotheses. The first family includes hypotheses about the testing of change from Baseline in PANSS total score at Week 6 between each of the SEP-363856 dose levels vs. placebo. The second family of hypotheses are about the testing of change from Baseline in CGI-S score at Week 6 between each of the SEP-363856 dose levels vs. placebo.
Condition or Disease Intervention/Treatment
  • Schizophrenia
  • Drug: SEP-363856 75mg
  • Drug: SEP-363856 100mg
  • Drug: Placebo

Study Design

Study TypeInterventional
Actual Enrollment464 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingQuadruple
Primary PurposeTreatment
Official TitleA Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia
Study Start DateSeptember 30, 2019
Actual Primary Completion DateJune 14, 2023
Actual Study Completion DateJune 14, 2023

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • SEP-363856 75mg
    • SEP-363856 75mg dosed once daily
  • Drug: SEP-363856 75mg
    • SEP-363856 75mg tablet dosed once daily
  • SEP-363856 100mg
    • SEP-363856 100mg dosed once daily
  • Drug: SEP-363856 100mg
    • Placebo
      • Placebo dosed once daily
    • Drug: Placebo

      Outcome Measures

      Primary Outcome Measures

      1. Change from Baseline in Positive and negative syndrome scale (PANSS) total score at Endpoint (Week 6) [Baseline and Week 6]
        PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.

      Secondary Outcome Measures

      1. Change from Baseline in Clinical Global Impressions - Severity (CGI-S) score at Endpoint (Week 6) [Baseline and Week 6]
        The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.

      Eligibility Criteria

      Ages Eligible for Study 18 Years to 65 Years (Adult, Older Adult)
      Sexes Eligible for Study All
      Accepts Healthy Volunteers No
      Inclusion Criteria
      • Male or female subject between 18 to 65 years of age (inclusive) at the time of consent.
      • Subject must give written informed consent and privacy authorization prior to participation in the study; adolescents must also provide informed assent.
      • Subject meets DSM-5 criteria for schizophrenia as established by clinical interview at screeing.
      • Subject must have a CGI-S score ≥ 4
      • Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content
      • Subject has an acute exacerbation of psychotic symptoms (persisting no longer than 2 months prior to providing informed consent).
      • Subject has marked deterioration of functioning in one or more areas.
      • Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, PE, neurological examination, vital signs, ECG and clinical laboratory values.
      Exclusion Criteria
      • Subject has a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms are not the primary focus of treatment.
      • Subject is at significant risk of harming self, others, or objects based on Investigator's judgment.
      • Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study
      • Female subject who is pregnant or lactating
      • Subject has any clinically significant abnormal laboratory value(s) at Screening as determined by investigator.

      Contacts and Locations

      Sponsors and Collaborators Otsuka Pharmaceutical Development & Commercialization, Inc.
      Locations
      • Woodland Research Northwest | Rogers, Arkansas, United States, 72758
      • Advanced Research Center, Inc. | Anaheim, California, United States, 92805
      • Clinical Innovations, Inc. | Bellflower, California, United States, 90706
      • ProScience Research Group | Culver City, California, United States, 90230
      • Collaborative Neuroscience Network | Long Beach, California, United States, 90806
      • California Neuropsychopharmacology Clinical Research Institute | San Diego, California, United States, 92102
      • Schuster Medical Research Institute | Sherman Oaks, California, United States, 91403
      • Larkin Behavioral Health Services | Hollywood, Florida, United States, 33021
      • South Florida Research Phase I-IV, INC. | Miami Springs, Florida, United States, 33166
      • Atlanta Center for Medical Research | Atlanta, Georgia, United States, 30331
      • iResearch Atlanta, LLC | Decatur, Georgia, United States, 30030
      • Pillar Clinical Research | Chicago, Illinois, United States, 60641
      • Lake Charles Clinical Trials | Lake Charles, Louisiana, United States, 70629
      • CBH Health, LLC | Gaithersburg, Maryland, United States, 20877
      • Arch Clinical Trials, LLC | Saint Louis, Missouri, United States, 63125
      • Hassman Research Institute | Marlton, New Jersey, United States, 08053
      • New York State Psychiatric Institute | New York, New York, United States, 10032
      • Pillar Clinical Research | Richardson, Texas, United States, 75080
      • Mental Health Centre, Prof. Dr. Ivan Temkov, Burgas EOOD, Department for Treatment of Emergency Psychiatric Conditions | Burgas, Bulgaria, 8000
      • State Psychiatric Hospital - Kardzhali, First Woman Department, Third Men Deparment | Kardzhali, Bulgaria, 6600
      • State Psychiatric Hospital Sv. Ivan rilski-Department General Psychiatry for Adults "closed" Type -Men, Department General Psychiatry for Adults, "Closed" Type - Women | Novi Iskar, Bulgaria, 1282
      • UMHAT Sveti Georgi EAD | Plovdiv, Bulgaria, 4000
      • Mental Health Center - Sofia EOOD Unit for Active Treatment of Persons with Serious Mental Disorders | Sofia, Bulgaria, 1202
      • UMHAT Alexandrovska EAD Second Department of Pshychiatry at Clinic of Psychiatry | Sofia, Bulgaria, 1431
      • Psychiatric Hospital "Sveti Ivan" | Zagreb, Croatia, 10090
      • LTD Psychoeurological Hospital of Daugavpils | Daugavpils, Latvia, LV-5417
      • SLLC Riga Centre of Psychiatry and Narcology | Riga, Latvia, LV-1005
      • SLLC Psychoneurological Hospital of Strenci | Strenci, Latvia, LV-4730
      • State Budgetary Healthcare Institution of Arkhangelsk region "Arkhangelsk clinical psychiatric hospital" | Arkhangelsk, Russian Federation, 163530
      • State Healthcare Institution "Psychiatric Hospital of Engels" of MoH of Saratov Region, departments № 1 and 3, 166 | Engels, Russian Federation, 413124
      • State Public Institution of Healthcare Leningrad Regional Psychoneurological Dispensary | Leningrad, Russian Federation, 188820
      • State Budgetary Institution of Healthcare of Moscow "Psychiatric Clinical Hospital #1 named after N.A. Alekseev of Department of Healthcare of Moscow | Moscow, Russian Federation, 117152
      • State Budgetary Institution of Healthcare of Moscow "Psychiatric Hospital No. 5" | Moscow, Russian Federation, 141371
      • Saint Petersburg State Budgetary Institution of Healthcare "Psychiatric Hospital named after P.P. Kashchenko, inpatient No 2 leg add | Saint Petersburg, Russian Federation, 190005
      • FSBI- "NMRC of Psychiatry and Neurology named after V.M. Bekhterev" MoH RF3 | Saint Petersburg, Russian Federation, 192019
      • Saint Petersburg State Public Institution of Healthcare "City Psychiatric Hospital #3 named after I.I. Skvortsov-Stepanov" | Saint Petersburg, Russian Federation, 197341
      • State Institution of Healthcare "Saratov City Clinical Hospital #2 named after V.I. Razumovskiy" 20 and 21 departments | Saratov, Russian Federation, 410028
      • State Institution of Healthcare Regional Clinical Psychiatric Hospital of Saint Sofia | Saratov, Russian Federation, 410060
      • FSBI "NMRC of Psychiatry and Neurology named after V.M. Bekterev" MoH RF | St. Petersburg, Russian Federation, 192019
      • State Budgetary Healthcare Institution of Stavropol region "Stavropol Region Psychiatric Hospital # 2" | Stavropol, Russian Federation, 357034
      • Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of Russian Academy of Sciences", | Tomsk, Russian Federation, 634014
      • Clinic of Psychiatry, Clinical Center of Serbia, | Belgrade, Serbia, 11000
      • Clinic of Psychiatry, Clinical Center of Serbia | Belgrade, Serbia, 11000
      • Clinical Center "Dr Dragisa Misovic- Dedinje" | Belgrade, Serbia, 11000
      • Special Hospital for Psychiatric Diseases "Kovin" | Kovin, Serbia, 26220
      • Special Neuropsychiatric Hospital Kovin | Kovin, Serbia, 26220
      • Clinic of Psychiatry, clinical Center Kragujevac | Kragujevac, Serbia, 34000
      • University Clinical Center Kragujevac, Clinic of Psychiatry | Kragujevac, Serbia, 34000
      • University Clinical Center Nis, Clinic of Psychiatry | Nis, Serbia, 18000
      • Special Hospital for Psychiatric Disease Sveti Vracevi | Novi Knezevac, Serbia, 23330
      • Special Hospital for Psychiatric Diseases "SVeti Vracevi" | Novi Knezevac, Serbia, 23330
      • Special Hospital for Psychiatric Diseases "Dr Slavoljub Bakalovic" | Vrsac, Serbia, 26300
      • 46 Academician Pavlov St | Kharkiv, Ukraine, 61068
      • State Institution Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine, Department of Boundary Psychiatry | Kharkiv, Ukraine, 61068
      • Communica Noncommercial Enterprise Kherson Regional Institution of Psychiatric Care Assistance of Kherson Regional Council, Male Department of Psychiatry #3, Female Department of Psychiatry #10 | Kherson, Ukraine, 73488
      • Kyev Clinical Hospital on Railway Station #1 of Healthcare Center branch of JSC "Ukrainian railway" Department of Psychoneurology | Kyiv, Ukraine, 01030
      • National Military and Medical Clinical Center, The Main Military Clinical Hospital, Psychiatric Clinic with Wards for Narcological Patients | Kyiv, Ukraine, 01133
      • Communal Institution of Kyiv Regional Council Regional Psychiatric and Narcological Medical Association, Male Department #10, Female Department #2 | Kyiv, Ukraine, 08631
      • Communal Non-commercial Enterprise Kyiv City Psychoneurological Hospital #3 of Executive Body of Kyiv City Council (Kyiv City State Administration), General Psychiatric Department #4 , | Kyiv, Ukraine, 08631
      • Communal Non-commercial Enterprise Kyiv City Psychoneurological Hospital #3 of Executive Body of Kyiv City Council (Kyiv City State Administration), General Psychiatric Department #4 | Kyiv, Ukraine, 08631
      • Communal Noncommercial Enterprise of Lviv Regional Concil Lviv Regional Clinical Psychiatric Hospital, Department #20 | Lviv, Ukraine, 79021
      • Communal Institution O.I. Yuschenko Vinnytsia Regional Psychoneurological Hospital, Male Department #21, Female Department #15, M.I. Pyrogov Vinnytsia National Medical University, Chair of Psychiatry, Narcology and Psychotherapy with Postgraduate Educatio | Vinnytsia, Ukraine, 21005

      More Information

      Additional Relevant MeSH Terms

      • Schizophrenia
      • Schizophrenia Spectrum and Other Psychotic Disorders
      • Mental Disorders